UK Markets closed

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
1,319.60+19.00 (+1.46%)
At close: 4:35PM BST
Full screen
Previous close1,300.60
Open1,317.40
Bid1,300.00 x 0
Ask1,320.00 x 0
Day's range1,304.20 - 1,322.40
52-week range1,190.80 - 1,748.55
Volume6,592,342
Avg. volume11,056,900
Market cap66.394B
Beta (5Y monthly)0.36
PE ratio (TTM)11.57
EPS (TTM)114.10
Earnings date28 Apr 2021
Forward dividend & yield0.80 (6.06%)
Ex-dividend date18 Feb 2021
1y target est1,644.50
  • Motley Fool

    How Important Is Novavax's COVID Vaccine Manufacturing Deal With GlaxoSmithKline?

    GlaxoSmithKline (NYSE: GSK) has teamed up with several other companies to develop COVID-19 vaccine candidates. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how important this manufacturing deal with GlaxoSmithKline is for Novavax. Keith Speights: Novavax -- the ticker there is NVAX -- announced this week that it's teamed up with GlaxoSmithKline -- ticker there is GSK -- to support the manufacturing of its COVID vaccine in the United Kingdom.

  • Motley Fool

    Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?

    GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.

  • 3 Stocks That Could Suffer if Biden Gives In to This Pressure
    Motley Fool

    3 Stocks That Could Suffer if Biden Gives In to This Pressure

    A proposal currently before the World Trade Organization would waive patent rights on COVID-19 vaccines and treatments in an effort to help low-income nations. Several top Democrats appear to support the move, although the Biden administration has yet to state a position publicly. Despite the push, the president may be hesitant to override patents for pharmaceuticals.